Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corp (NQ: BPMC )

61.21 -7.34 (-10.71%)
Streaming Delayed Price Updated: 2:39 PM EDT, Aug 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,898,100
Open 53.74
Bid (Size) 61.13 (3)
Ask (Size) 61.29 (3)
Prev. Close 68.55
Today's Range 52.00 - 61.51
52wk Range 43.46 - 116.60
Shares Outstanding 59,719,570
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Sanofi, Children's Place And Some Other Big Stocks Moving Lower On Wednesday
  Embark Technology, Inc. (NASDAQ: EMBK) fell 25.1% to $12.40. Embark Technology reported the completion of reverse stock split. 
Via Benzinga
Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday's Mid-Day Session
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus... 
Via Benzinga

Performance

YTD
-44.39%
-44.39%
1 Month
+16.68%
+16.68%
3 Month
+4.69%
+4.69%
6 Month
-26.44%
-26.44%
1 Year
-34.16%
-34.16%

More News

Read More
Data From Blueprint Medicines' Blood Disorder Trial Fails To Lift Shares
Via Benzinga
Where Blueprint Medicines Stands With Analysts
Via Benzinga
U.S. Stocks Open Lower; Nasdaq Down 150 Points
Via Benzinga
Blueprint Medicines Stock Is Getting Hammered Wednesday: What's Happening?
Via Benzinga
Blueprint Medicines Stock Hammered As 'Long-Awaited' Test Results Disappoint
Via Investor's Business Daily
Blueprint Medicines Shares Fall After Topline Results From Late-Stage Neoplastic Disorder Study
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Blueprint Medicines: Q2 Earnings Insights
Via Benzinga
4 Analysts Have This to Say About Blueprint Medicines
Via Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Via Benzinga
A Preview Of Blueprint Medicines's Earnings
Via Benzinga
3 Biotech Stock Picks From This Wedbush Analyst
Via Benzinga
Week In Review: Qiming Closes $3.2 Billion For China Healthcare And Technology Investments
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022
Via Benzinga
This Analyst Thinks Blueprint Medicines' Non-Dilutive Funding 'Deflates M&A Speculation'
Via Benzinga
What 7 Analyst Ratings Have To Say About Blueprint Medicines
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2022
Via Benzinga
SVB Leerink Maintains Market Perform Rating for Blueprint Medicines: Here's What You Need To Know
Via Benzinga
10 Biggest Price Target Changes For Monday
Via Benzinga
91 Biggest Movers From Friday
Via Benzinga
44 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2022
Via Benzinga
What You Missed On Wall Street On Thursday
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.